Update on antiplatelet therapy for stroke prevention

Ralph L Sacco, Mitchell S. Elkind

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The high rates of mortality and long-term disability associated with ischemic stroke, coupled with its prevalence, necessitate good, long-term preventive strategies. Risk-factor management is effective for individuals with preclinical and clinical cerebrovascular disease. Patients suffering from a transient ischemic attack or stroke are particularly vulnerable to subsequent stroke. Most of these individuals are candidates for antiplatelet treatment to prevent a recurrence. Available antiplatelet therapies include aspirin, ticlopidine, and clopidogrel. The combination of low-dose aspirin plus extended-release dipyridamole has been shown to offer safe, effective antiplatelet therapy for appropriate patients. In the second European Stroke Prevention Study, the combination was found to be significantly more effective than either drug alone, at the cost of relatively few treatment- related adverse effects. This combination is currently recommended as one of the first-line treatments for stroke prevention after first transient ischemic attack or stroke.

Original languageEnglish
Pages (from-to)1579-1582
Number of pages4
JournalArchives of Internal Medicine
Volume160
Issue number11
StatePublished - Jun 12 2000
Externally publishedYes

Fingerprint

Stroke
clopidogrel
Transient Ischemic Attack
Therapeutics
Ticlopidine
Cerebrovascular Disorders
Risk Management
Aspirin
Recurrence
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Update on antiplatelet therapy for stroke prevention. / Sacco, Ralph L; Elkind, Mitchell S.

In: Archives of Internal Medicine, Vol. 160, No. 11, 12.06.2000, p. 1579-1582.

Research output: Contribution to journalArticle

Sacco, Ralph L ; Elkind, Mitchell S. / Update on antiplatelet therapy for stroke prevention. In: Archives of Internal Medicine. 2000 ; Vol. 160, No. 11. pp. 1579-1582.
@article{3c416ac39c2940e886e37390a9ac37d1,
title = "Update on antiplatelet therapy for stroke prevention",
abstract = "The high rates of mortality and long-term disability associated with ischemic stroke, coupled with its prevalence, necessitate good, long-term preventive strategies. Risk-factor management is effective for individuals with preclinical and clinical cerebrovascular disease. Patients suffering from a transient ischemic attack or stroke are particularly vulnerable to subsequent stroke. Most of these individuals are candidates for antiplatelet treatment to prevent a recurrence. Available antiplatelet therapies include aspirin, ticlopidine, and clopidogrel. The combination of low-dose aspirin plus extended-release dipyridamole has been shown to offer safe, effective antiplatelet therapy for appropriate patients. In the second European Stroke Prevention Study, the combination was found to be significantly more effective than either drug alone, at the cost of relatively few treatment- related adverse effects. This combination is currently recommended as one of the first-line treatments for stroke prevention after first transient ischemic attack or stroke.",
author = "Sacco, {Ralph L} and Elkind, {Mitchell S.}",
year = "2000",
month = "6",
day = "12",
language = "English",
volume = "160",
pages = "1579--1582",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Update on antiplatelet therapy for stroke prevention

AU - Sacco, Ralph L

AU - Elkind, Mitchell S.

PY - 2000/6/12

Y1 - 2000/6/12

N2 - The high rates of mortality and long-term disability associated with ischemic stroke, coupled with its prevalence, necessitate good, long-term preventive strategies. Risk-factor management is effective for individuals with preclinical and clinical cerebrovascular disease. Patients suffering from a transient ischemic attack or stroke are particularly vulnerable to subsequent stroke. Most of these individuals are candidates for antiplatelet treatment to prevent a recurrence. Available antiplatelet therapies include aspirin, ticlopidine, and clopidogrel. The combination of low-dose aspirin plus extended-release dipyridamole has been shown to offer safe, effective antiplatelet therapy for appropriate patients. In the second European Stroke Prevention Study, the combination was found to be significantly more effective than either drug alone, at the cost of relatively few treatment- related adverse effects. This combination is currently recommended as one of the first-line treatments for stroke prevention after first transient ischemic attack or stroke.

AB - The high rates of mortality and long-term disability associated with ischemic stroke, coupled with its prevalence, necessitate good, long-term preventive strategies. Risk-factor management is effective for individuals with preclinical and clinical cerebrovascular disease. Patients suffering from a transient ischemic attack or stroke are particularly vulnerable to subsequent stroke. Most of these individuals are candidates for antiplatelet treatment to prevent a recurrence. Available antiplatelet therapies include aspirin, ticlopidine, and clopidogrel. The combination of low-dose aspirin plus extended-release dipyridamole has been shown to offer safe, effective antiplatelet therapy for appropriate patients. In the second European Stroke Prevention Study, the combination was found to be significantly more effective than either drug alone, at the cost of relatively few treatment- related adverse effects. This combination is currently recommended as one of the first-line treatments for stroke prevention after first transient ischemic attack or stroke.

UR - http://www.scopus.com/inward/record.url?scp=0034640939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034640939&partnerID=8YFLogxK

M3 - Article

C2 - 10847250

AN - SCOPUS:0034640939

VL - 160

SP - 1579

EP - 1582

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 11

ER -